168 related articles for article (PubMed ID: 38003293)
1. Association of
Justo-Garrido M; López-Saavedra A; Alcaraz N; Cortés-González CC; Oñate-Ocaña LF; Caro-Sánchez CHS; Castro-Hernández C; Arriaga-Canon C; Díaz-Chávez J; Herrera LA
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003293
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid receptor GPR120 promotes breast cancer chemoresistance by upregulating ABC transporters expression and fatty acid synthesis.
Wang X; He S; Gu Y; Wang Q; Chu X; Jin M; Xu L; Wu Q; Zhou Q; Wang B; Zhang Y; Wang H; Zheng L
EBioMedicine; 2019 Feb; 40():251-262. PubMed ID: 30738829
[TBL] [Abstract][Full Text] [Related]
3. Transcriptome Analysis Identifies GATA3-AS1 as a Long Noncoding RNA Associated with Resistance to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients.
Contreras-Espinosa L; Alcaraz N; De La Rosa-Velázquez IA; Díaz-Chávez J; Cabrera-Galeana P; Rebollar-Vega R; Reynoso-Noverón N; Maldonado-Martínez HA; González-Barrios R; Montiel-Manríquez R; Bautista-Sánchez D; Castro-Hernández C; Alvarez-Gomez RM; Jiménez-Trejo F; Tapia-Rodríguez M; García-Gordillo JA; Pérez-Rosas A; Bargallo-Rocha E; Arriaga-Canon C; Herrera LA
J Mol Diagn; 2021 Oct; 23(10):1306-1323. PubMed ID: 34358678
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy.
Baxter DE; Kim B; Hanby AM; Verghese ET; Sims AH; Hughes TA
Clin Breast Cancer; 2018 Dec; 18(6):481-488. PubMed ID: 30055962
[TBL] [Abstract][Full Text] [Related]
5. Identification of hub genes associated with EMT-induced chemoresistance in breast cancer using integrated bioinformatics analysis.
Kaur B; Mukhlis Y; Natesh J; Penta D; Musthapa Meeran S
Gene; 2022 Jan; 809():146016. PubMed ID: 34655723
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients.
Turiján-Espinoza E; Ruíz-Rodríguez VM; Uresti-Rivera EE; Martínez-Leija E; Zermeño-Nava JJ; Guel-Pañola A; Romano-Moreno S; Vargas-Morales JM; Portales-Pérez DP
Cancer Chemother Pharmacol; 2021 Jun; 87(6):843-853. PubMed ID: 33740100
[TBL] [Abstract][Full Text] [Related]
7. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.
Montagut C; Tusquets I; Ferrer B; Corominas JM; Bellosillo B; Campas C; Suarez M; Fabregat X; Campo E; Gascon P; Serrano S; Fernandez PL; Rovira A; Albanell J
Endocr Relat Cancer; 2006 Jun; 13(2):607-16. PubMed ID: 16728586
[TBL] [Abstract][Full Text] [Related]
8. Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women.
Singh LC; Chakraborty A; Mishra AK; Devi TR; Sugandhi N; Chintamani C; Bhatnagar D; Kapur S; Saxena S
Med Oncol; 2012 Jun; 29(2):539-46. PubMed ID: 21528410
[TBL] [Abstract][Full Text] [Related]
9. Targeting PKM2 promotes chemosensitivity of breast cancer cells in vitro and in vivo.
Wang Y; Zhao H; Zhao P; Wang X
Cancer Biomark; 2021; 32(2):221-230. PubMed ID: 34092620
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy.
Végran F; Boidot R; Oudin C; Riedinger JM; Bonnetain F; Lizard-Nacol S
Clin Cancer Res; 2006 Oct; 12(19):5794-800. PubMed ID: 17020986
[TBL] [Abstract][Full Text] [Related]
11. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer.
Chen S; Liu Y; Ouyang QW; Huang L; Luo RC; Shao ZM
Ann Surg Oncol; 2015 Jan; 22(1):32-9. PubMed ID: 25012266
[TBL] [Abstract][Full Text] [Related]
13. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression.
Zhang Z; Qiu N; Yin J; Zhang J; Liu H; Guo W; Liu M; Liu T; Chen D; Luo K; Li H; He Z; Liu J; Zheng G
Theranostics; 2020; 10(10):4290-4307. PubMed ID: 32292495
[No Abstract] [Full Text] [Related]
14. Stromal Cell Signature Associated with Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Katayama MLH; Vieira RADC; Andrade VP; Roela RA; Lima LGCA; Kerr LM; Campos AP; Pereira CAB; Serio PAMP; Encinas G; Maistro S; Petroni MAL; Brentani MM; Folgueira MAAK
Cells; 2019 Dec; 8(12):. PubMed ID: 31817155
[TBL] [Abstract][Full Text] [Related]
15. Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer.
Alamgeer M; Ganju V; Kumar B; Fox J; Hart S; White M; Harris M; Stuckey J; Prodanovic Z; Schneider-Kolsky ME; Watkins DN
Breast Cancer Res; 2014 Apr; 16(2):R44. PubMed ID: 24762066
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional shift identifies a set of genes driving breast cancer chemoresistance.
Vera-Ramirez L; Sanchez-Rovira P; Ramirez-Tortosa CL; Quiles JL; Ramirez-Tortosa M; Lorente JA
PLoS One; 2013; 8(1):e53983. PubMed ID: 23326553
[TBL] [Abstract][Full Text] [Related]
17. miR-1275 targets MDK/AKT signaling to inhibit breast cancer chemoresistance by lessening the properties of cancer stem cells.
Han X; Li M; Xu J; Fu J; Wang X; Wang J; Xia T; Wang S; Ma G
Int J Biol Sci; 2023; 19(1):89-103. PubMed ID: 36594100
[TBL] [Abstract][Full Text] [Related]
18. TFEB, SIRT1, CARM1, Beclin-1 expression and PITX2 methylation in breast cancer chemoresistance: a retrospective study.
Bertozzi S; Londero AP; Viola L; Orsaria M; Bulfoni M; Marzinotto S; Corradetti B; Baccarani U; Cesselli D; Cedolini C; Mariuzzi L
BMC Cancer; 2021 Oct; 21(1):1118. PubMed ID: 34663249
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients.
Park S; Shimizu C; Shimoyama T; Takeda M; Ando M; Kohno T; Katsumata N; Kang YK; Nishio K; Fujiwara Y
Breast Cancer Res Treat; 2006 Sep; 99(1):9-17. PubMed ID: 16752223
[TBL] [Abstract][Full Text] [Related]
20. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
Chen S; Huang L; Chen CM; Shao ZM
Oncotarget; 2015 Jul; 6(20):18174-82. PubMed ID: 26053183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
